Related Experiment Video
Updated: Jun 9, 2026
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
[Evaluation of MicroScan Synergies plus Positive Combo 3 Panels for identification and antimicrobial susceptibility
1Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Background:
Few studies have evaluated the performance of the recently introduced MicroScan Synergies plus Positive Combo 3 Panels (SIPC3) (Dade Behring Inc., USA). We evaluated the clinical efficacy of the panels in identification (ID) and antimicrobial susceptibility testing (AST) of Staphylococcus aureus and enterococci.
Methods:
To evaluate the panels' accuracy of identification, the results obtained using the test panels were compared with those obtained by using conventional biochemical tests in conjunction with VITEK 2 system (bio-Merieux, USA). In addition, the AST results obtained using the panels were compared with those obtained by performing CLSI broth microdilution.
Results:
The overall agreement between the approaches for the ID of S. aureus and enterococci was 100% and 96%, respectively. The categorical and essential agreements (CA and EA) for S. aureus were 98%, each. Very major errors (VME), major errors (ME), and minor error (mE) for S. aureus were 0.45%, 0.3%, and 4.2%, respectively. The majority of VMEs were for oxacillin (8.6%), penicillin (2.0%), erythromycin (7.9%), clindamycin (3.8%), and tetracycline (4.1%). For enterococci, the CA, EA, VME, ME, and mE were 88.8%, 93.7%, 4.4%, 0%, and 2.8%, respectively. The 80.5% (29/36) of Enterococcus faecium had concordant ID with the reference. Most of the categorical errors (3 VMEs and 14 mEs) were observed for quinupristin/dalfopristin (Synercid; Catalytica Pharmaceuticals Inc., USA).
Conclusions:
The panels compared favorably with conventional methods for the ID and AST of S. aureus. However, we expected a better performance for ID of E. faecium and AST using Synercid.
Insights
The MicroScan Synergies plus Positive Combo 3 Panels (SIPC3) show high accuracy for Staphylococcus aureus identification and antimicrobial susceptibility testing. Performance for enterococci identification and Synercid antimicrobial susceptibility testing requires improvement.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Diagnostic Technology
Background:
- Limited data exists on the performance of the MicroScan Synergies plus Positive Combo 3 Panels (SIPC3).
- Evaluation of diagnostic panels is crucial for accurate patient care.
Purpose of the Study:
- To assess the clinical efficacy of SIPC3 panels for identifying Staphylococcus aureus and enterococci.
- To evaluate the antimicrobial susceptibility testing (AST) performance of SIPC3 panels for these bacteria.
Main Methods:
- Compared SIPC3 panel results against conventional biochemical tests and the VITEK 2 system for bacterial identification.
- Validated AST results from SIPC3 panels using the CLSI broth microdilution method.
Main Results:
- SIPC3 achieved 100% agreement for S. aureus identification and 96% for enterococci.
- High categorical and essential agreement (98%) for S. aureus AST, with minimal errors.
- Enterococci identification showed 88.8% categorical agreement, with notable discrepancies for Enterococcus faecium and quinupristin/dalfopristin susceptibility.
Conclusions:
- SIPC3 panels demonstrate favorable performance for S. aureus identification and AST compared to conventional methods.
- Further optimization is needed for reliable identification of E. faecium and AST of enterococci, particularly with quinupristin/dalfopristin.
Related Concept Videos
01:24Automated Microbial Diagnostics
01:25Rapid Identification of Pathogens
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:25Clinical Significance of Antibiotic Resistance